Skip to main content
McMaster University Menu Search

Immunotherapy for Recurrent Glioblastoma

A promising lead panel of biotherapeutic modalities will ultimately be translated into early clinical development, generating targeted therapies for glioblastoma patients.


The overall goal of this project is to identify new therapeutic targets that drive clonal evolution in treatment-refractory glioblastoma (GBM). The aim is to develop novel immunotherapies (Monoclonal IgGs, Bispecific T-cell engagers and Chimeric antigen receptor T-cells) that harness the immune system and target specific cell surface receptors on GBM cells.

In building new biotherapeutics against novel cancer targets and in performing preclinical testing in our patient-derived animal model of treatment-resistant GBM, we will generate a translational pipeline from initial target discovery.

Collaborators

Picture Name Organization
Sachdev Sidhu, PhD Picture Sachdev Sidhu, PhD Professor, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto
Jason Moffat, PhD Picture Jason Moffat, PhD Associate Professor, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto

Funders

Impacts

Sheila Singh

Sheila Singh

Principal Investigator